Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 6/20 | 1.00 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.69 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543235 | 1.00 | DGAT1 (1.00) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3541237 | 0.95 | DGAT1 (0.90) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3539839 | 0.95 | DGAT1 (0.90) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3542335 | 0.95 | DGAT1 (0.90) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL16969247 | 0.92 | DGAT1 (1.00) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3549264 | 0.92 | DGAT1 (0.85) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3549262 | 0.92 | DGAT1 (0.85) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3545182 | 0.92 | DGAT1 (0.85) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL3545179 | 0.92 | DGAT1 (0.85) | DGAT1SOAT1DGAT2ACAT1 | |
| SCHEMBL27775852 | 0.91 | DGAT1 (0.83) | DGAT1SOAT1DGAT2ACAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154718-A | Functional hydrogel loaded with diacylglycerol acyltransferase inhibitor as well as preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2025-06-17 | — | — | CN | claimed |
| WO-2025078630-A1 | DIACYLGLYCEROL-ACYLTRANSFERASE 1 INHIBITOR FOR USE IN A METHOD OF TREATING CANCER IN A HUMAN FEMALE PATIENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-04-17 | — | — | WO | claimed |
| EP-2041101-A1 | CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO]-1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO]PH ENYL } CYCLOHEXYL) ACETIC ACID | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| WO-2007144571-A1 | CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO] -1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO] PH ENYL } CYCLOHEXYL) ACETIC ACID | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | claimed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-12419847-B2 | Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-09-23 | — | — | US | disclosed |
| CN-120154718-A | Functional hydrogel loaded with diacylglycerol acyltransferase inhibitor as well as preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2025-06-17 | — | — | CN | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025078630-A1 | DIACYLGLYCEROL-ACYLTRANSFERASE 1 INHIBITOR FOR USE IN A METHOD OF TREATING CANCER IN A HUMAN FEMALE PATIENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-04-17 | — | — | WO | disclosed |
| US-20250011722-A1 | HEPATIC ORGANOIDS | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2025-01-09 | — | — | US | disclosed |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-05-02 | — | — | US | disclosed |
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007144571-A1 | CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO] -1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO] PH ENYL } CYCLOHEXYL) ACETIC ACID | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1858592-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | Allergan, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006101867-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | STAMBP, HSPBP1, ECPAS | DGAT1 4259/4885SOAT1 4016/4885DGAT2 4299/4885 |
| US-12419847-B2 | Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy | MAPT, LCAT, ACAT2 | DGAT1 80/4885SOAT1 74/4885DGAT2 34/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885SOAT1 7/4885DGAT2 2/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | DGAT1 3915/4885SOAT1 3483/4885DGAT2 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.